Kallmann syndrome in women: From genes to diagnosis and treatment

Gynecological Endocrinology

Volumn 29, Issue 4, 2013, Pages 296-300

  Meczekalski, Blazej ^a   Podfigurna Stopa, Agnieszka ^a   Smolarczyk, Roman ^b   Katulski, Krzysztof ^a   Genazzani, Andrea R ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Amenorrhea; Gonadotropin releasing hormone; Hypogonadotropic hypogonadism; Kallmann syndrome; Smell

Indexed keywords

ANOSMIN 1; CELL ADHESION MOLECULE; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 7; DNA BINDING PROTEIN; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR 2; ESTRADIOL; ESTROGEN; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FOLLITROPIN; GESTAGEN; GONADORELIN; GONADOTROPIN; KAL1 PROTEIN; LUTEINIZING HORMONE; PROKINETICIN 2; PROKINETICIN RECEPTOR 2; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ANOSMIA; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BLINDNESS; BONE MASS; BREAST DEVELOPMENT; CELL MIGRATION; CLEFT LIP; CLEFT PALATE; COLOR BLINDNESS; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FOLLITROPIN BLOOD LEVEL; FRAMESHIFT MUTATION; GENETIC ANALYSIS; GLOMERULUS FILTRATION; GONADOTROPIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HYPODONTIA; HYPOGONADOTROPIC HYPOGONADISM; HYPOSMIA; KALLMANN SYNDROME; LUTEINIZING HORMONE BLOOD LEVEL; NERVE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE ATROPHY; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK REDUCTION; SYNDROME CHARGE; SYNKINESIS; TELENCEPHALON;

DNA HELICASES; DNA-BINDING PROTEINS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLAST GROWTH FACTOR 8; GASTROINTESTINAL HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; KALLMANN SYNDROME; MUTATION; NERVE TISSUE PROTEINS; NEUROPEPTIDES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE;

EID: 84875664980     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.752459     Document Type: Article

References (51)

1. de San Juan MA. Falta total de los nervios olfactorios con anosmía en un individuo en quien existía una atrofía congénita de los testículos y miembro viril. Siglo Med 1856;131:211-21.
2. Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidsm. Am J Mental Def 1944:48:203-36.
3. De Morsier G. Etudes sur les dysraphies cranio-encephaliques. I. Agenesie des lobes olfactifs (telencephaloschizis lateral) et des commissures calleuse et anterieure (telencephaloschizis median): la dysplasie olfacto-genitale. Schweizer Arch Neurol Neurochir Psych 1954:74:309-61.
4. Naftolin F, Harris GW, Bobrow M. Effect of purified luteinizing hormone releasing factor on normal and hypogonadotropic anosmic men. Nature 1971;232:496-7.
5. Santen RJ, Paulsen CA. Hypogonadotropic eunuchoidism. I. Clinical study of the mode of inheritance. J Clin Endocrinol Metab 1972;36:47-54.
6. Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971;173:1036-8.
7. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 1980;36:53-88.
8. Jeffcoate JL, Greenwood RH, Holland DT. Blood and urine clearance of luteinizing hormone releasing hormone in man measured by radioimmuno-assay. J Endocrinol 1974;60:305-14.
9. Gharib SD, Wierman ME, Shupnik MA, Chin WW. Molecular biology of the pituitary gonadotropins. Endocr Rev 1990;11:177-99.
10. Genazzani AR, Bernardi F, Monteleone P, et al. Neuropeptides, neurotransmitters, neurosteroids, and the onset of puberty. Ann NY Acad Sci 2000;900:1-9.
11. Tobet SA, Chickering TW, King JC, et al. Expression of gamma-aminobutyric acid and gonadotropin-releasing hormone during neuronal migration through the olfactory system. Endocrinology 1996;137:5415-20.
12. Schwanzel-Fukuda M, Bick D, Pfaff DW. Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Mol Brain Res 1989;6:311-26.
13. Quinton R, Hasan W, Grant W, et al. Gonadotropin-releasing hormone immunoreactivity in the nasal epithelia of adults with Kallmann's syndrome and isolated hypogonadotropic hypogonadism and in the early midtrimester human fetus. J Clin Endocrinol Metab 1997;82:309-14.
14. Wray S, Key S, Qualls R, Fueshko SM. A subset of peripherin positive olfactory axons delineates the luteinizing hormone releasing hormone neuronal migratory pathway in developing mouse. Dev Biol 1994;166:349-54.
15. Toba Y, Pakiam J, Wray S. Voltage-gated calcium channels in the developing GnRH-1 neuronal systems. Eur J Neurosci 2005;22: 79-92.
16. Silveira LF, Trarbach EB, Latronico AC. Genetics basis for GnRH-dependent pubertal disorders in humans Mol Cell Endocrinol 2010;324:30-8.
17. Ballabio A, Bardoni B, Carrozzo R, et al. Contiguous gene syndromes due to deletions in the distal short arm of the human X chromosome Proc Natl Acad Sci USA 1989;86:10001-5.
18. Legouis R, Hardelin JP, Levilliers J, et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991;67:423-35.
19. Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991;353:529-36.
20. Tsai PS, Gill JC. Mechanisms of disease: Insights into X-linked and autosomal-dominant Kallmann syndrome. Nat Clin Pract Endocrinol Metab 2006;2:160-71.
21. Trarbach EB, Silveira LG, Latronico AC. Genetic insights into human isolated gonadotropin deficiency. Pituitary 2007;10:381-91.
22. Ribeiro RS, Vieira TC, Abucham J. Reversible Kallmann syndrome: report of the first case with a KAL1 mutation and literature review. Eur J Endocrinol 2007;156:285-90.
23. Chen L, Deng CX. Roles of FGF signaling in skeletal development and human genetic diseases. Front Biosci. 2005;10: 1961-76.
24. Gill JC, Moenter SM, Tsai PS. Developmental regulation of gonadotropin-releasing hormone neurons by fibroblast growth factor signaling. Endocrinology 2004;145:3830-9.
25. Salenave S, Chanson P, Bry H, et al. Kallmann's syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. J Clin Endocrinol Metab 2008;93:758-63.
26. Pitteloud N, Quinton R, Pearce S, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonad-ism. J Clin Invest 2007;117:457-63.
27. Falardeau J, Chung WC, Beenken A, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008;118:2822-31.
28. Trarbach EB, Abreu AP, Silveira LF, et al. Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency. J Clin Endocrinol Metab 2010;95:3491-6.
29. Pagon RA, Graham Jr JM, Zonana J, Yong SL. Coloboma, congenital heart disease, and choanal atresia with multiple anomalies: CHARGE association. J Pediatr 1981;99:223-7.
30. Vissers LE, van Ravenswaaij CM, Admiraal R, et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 2004;36:955-7.
31. Kim HG, Kurth I, Lan F, et al. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2008;83:511-9.
32. Jongmans MC, van Ravenswaaij-Arts CM, Pitteloud N, et al. CHD7 mutations in patients initially diagnosed with Kallmann syndrome-the clinical overlap with CHARGE syndrome. Clin Genet 2009;75:65-71.
33. Martin C, Balasubramanian R, Dwyer AA, et al. The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations. Endocr Rev 2011;32:225-46.
34. Cheng MY, Bullock CM, Li C, et al. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 2002;417:405-10.
35. Lin DC, Bullock CM, Ehlert FJ, et al. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem 2002;277:19276-80.
36. Matsumoto S, Yamazaki C, Masumoto KH, et al. Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. Proc Natl Acad Sci USA 2006;103:4140-5.
37. Pitteloud N, Zhang C, Pignatelli D, et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2007;104:17447-52.
38. Dodé C, Teixeira L, Levilliers J, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006;2:e175.
39. Leroy C, Fouveaut C, Leclercq S, et al. Biallelic mutations in the prokineticin-2 gene in two sporadic cases of Kallmann syndrome. Eur J Hum Genet 2008;16:865-8.
40. Bullock CM, Li JD, Zhou QY. Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists. Mol Pharmacol 2004;65:582-8.
41. Bouloux PM, Hu Y, MacColl G. Recent advances in the pathogenesis of Kallmann's syndrome. Prog Brain Res 2002; 141:79-83.
42. Kaplan JD, Bernstein JA, Kwan A, Hudgins L. Clues to an early diagnosis of Kallmann syndrome. Am J Med Genet A 2010;152A: 2796-801.
43. Meczekalski B, Podfigurna-Stopa A, Genazzani AR. Hypoestrogenism in young women and its influence on bone mass density. Gynecol Endocrinol 2010;26:652-7.
44. Bry-Gauillard H, Trabado S, Bouligand J, et al. Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics. Ann Endocrinol (Paris) 2010;71:158-62.
45. Pallais JC, Au M, Pitteloud N, Seminara S, et al. Kallmann syndrome. GeneReviews. 2011 Available at: http://www.ncbi.nlm. nih.gov/books/NBK1334/. Accessed December 22, 2011.
46. Dodé C, Hardelin JP. Kallmann syndrome. Eur J Hum Genet 2009;17:139-46.
47. MacColl G, Quinton R. Kallmann syndrome: bridging the gaps. J Pediatr Endocrinol Metab 2005;18:541-3.
48. Ravikumar B, Crowley Jr WF. Kallmann Syndrome and hypogona-dotropic Hypogonadism. Concluding remarks. Front Horm Res 2010;39:168-9.
49. Sato N, Katsumata N, Kagami M, et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004;89:1079-88.
50. Doty RL. Office procedures for quantitative assessment of olfactory function. Am J Rhinol 2007;21:460-73.
51. Martin K, Santoro N, Hall J, et al. Clinical review 15: management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab 1990;71:1081A-G.